MA34389B1 - Nouvelles aminopyrazoloquinazolines - Google Patents
Nouvelles aminopyrazoloquinazolinesInfo
- Publication number
- MA34389B1 MA34389B1 MA35577A MA35577A MA34389B1 MA 34389 B1 MA34389 B1 MA 34389B1 MA 35577 A MA35577 A MA 35577A MA 35577 A MA35577 A MA 35577A MA 34389 B1 MA34389 B1 MA 34389B1
- Authority
- MA
- Morocco
- Prior art keywords
- aminopyrazoloquinazolines
- new
- groups
- general formula
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention englobe les composés de formule générale (I) où les groupements R
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10170683 | 2010-07-23 | ||
PCT/EP2011/062683 WO2012010704A1 (fr) | 2010-07-23 | 2011-07-22 | Nouvelles aminopyrazoloquinazolines |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34389B1 true MA34389B1 (fr) | 2013-07-03 |
Family
ID=43037625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35577A MA34389B1 (fr) | 2010-07-23 | 2011-07-22 | Nouvelles aminopyrazoloquinazolines |
Country Status (22)
Country | Link |
---|---|
US (1) | US8735386B2 (fr) |
EP (1) | EP2595987B1 (fr) |
JP (1) | JP5991974B2 (fr) |
KR (1) | KR20130132394A (fr) |
CN (1) | CN103097388A (fr) |
AP (1) | AP2012006640A0 (fr) |
AR (1) | AR082850A1 (fr) |
AU (1) | AU2011281504A1 (fr) |
BR (1) | BR112013000107A2 (fr) |
CA (1) | CA2803467A1 (fr) |
CL (1) | CL2012003745A1 (fr) |
CO (1) | CO6670575A2 (fr) |
EA (1) | EA201201661A1 (fr) |
EC (1) | ECSP13012448A (fr) |
GE (1) | GEP20156289B (fr) |
MA (1) | MA34389B1 (fr) |
MX (1) | MX2013000821A (fr) |
PE (1) | PE20131143A1 (fr) |
SG (1) | SG187548A1 (fr) |
TW (1) | TW201217380A (fr) |
UY (1) | UY33526A (fr) |
WO (1) | WO2012010704A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013110585A1 (fr) | 2012-01-23 | 2013-08-01 | Boehringer Ingelheim International Gmbh | 5,8-dihydro-6h-pyrazolo[3,4-h]quinazolines en tant qu'inhibiteurs d'igf-lr/lr |
US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
MX2016006318A (es) * | 2013-11-15 | 2017-01-19 | Oncoceutics Inc | 7-bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pir ido[3,4-e]pirimidin-5(1h)-ona, sales de la misma y metodos de uso. |
MD3250208T2 (ro) | 2015-01-30 | 2021-02-28 | Oncoceutics Inc | 7-Benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1h)-onă și sărurile acesteia și utilizarea lor în terapie |
JP6664414B2 (ja) * | 2015-05-13 | 2020-03-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | IGF−1R/IR阻害薬としての新規5,8−ジメチル−9−フェニル−5,8−ジヒドロ−6H−ピラゾロ[3,4−h]キナゾリン−2−イル)−(1H−ピラゾール−3−イル)−アミン及び誘導体 |
CN108699067B (zh) * | 2016-11-11 | 2021-06-15 | 上海海雁医药科技有限公司 | 吡啶胺取代的杂三环化合物、其制法与医药上的用途 |
CN108484600B (zh) * | 2017-05-26 | 2022-12-13 | 江苏新元素医药科技有限公司 | 促尿酸***的urat1抑制剂 |
CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
US20210214358A1 (en) | 2018-04-24 | 2021-07-15 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Cdk4/6 inhibitor and pharmaceutically acceptable salt and polymorph thereof and use thereof |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
WO2020160321A1 (fr) * | 2019-01-30 | 2020-08-06 | Yale University | Composés, compositions et méthodes de traitement de la fibrose |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
WO2020180959A1 (fr) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Composés de pyrazolyl pyrimidinylamine en tant qu'inhibiteurs de cdk2 |
SG11202108752YA (en) * | 2019-03-07 | 2021-09-29 | BioNTech SE | Process for the preparation of a substituted imidazoquinoline |
WO2020205560A1 (fr) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Composés sulfonylamides utilisés comme inhibiteurs de la cdk2 |
JP2022531094A (ja) * | 2019-04-19 | 2022-07-06 | ファウント バイオ, インコーポレイテッド | 皮膚内への活性剤の送達および保持 |
WO2020223558A1 (fr) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Composés aminés tricycliques en tant qu'inhibiteurs de cdk2 |
WO2020223469A1 (fr) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer |
EP4013750A1 (fr) | 2019-08-14 | 2022-06-22 | Incyte Corporation | Composés imidazolyl-pyrimidinylamines utilisés comme inhibiteurs de la cdk2 |
WO2021072232A1 (fr) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Amines bicycliques utilisées en tant qu'inhibiteurs de cdk2 |
JP2023529867A (ja) | 2020-06-05 | 2023-07-12 | キネート バイオファーマ インク. | 線維芽細胞増殖因子受容体キナーゼの阻害剤 |
CN111960974A (zh) * | 2020-08-28 | 2020-11-20 | 山东潍坊润丰化工股份有限公司 | 一种烯草酮中间体的合成方法 |
US20240140962A1 (en) * | 2021-02-08 | 2024-05-02 | Medshine Discovery Inc. | 5,6-dihydrothieno[3,4-h]quinazoline compound |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100258052B1 (ko) * | 1995-10-02 | 2000-08-01 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 5ht2c-수용체 길항제로서의 피리미딘 유도체 및 이를 포함하는 약물 |
GEP20094664B (en) | 2003-05-22 | 2009-04-10 | Nerviano Medical Sciences Srl | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
-
2011
- 2011-07-20 US US13/187,100 patent/US8735386B2/en active Active
- 2011-07-21 UY UY0001033526A patent/UY33526A/es not_active Application Discontinuation
- 2011-07-22 SG SG2013003645A patent/SG187548A1/en unknown
- 2011-07-22 GE GEAP201113008A patent/GEP20156289B/en unknown
- 2011-07-22 AU AU2011281504A patent/AU2011281504A1/en not_active Abandoned
- 2011-07-22 EA EA201201661A patent/EA201201661A1/ru unknown
- 2011-07-22 AR ARP110102670A patent/AR082850A1/es unknown
- 2011-07-22 BR BR112013000107A patent/BR112013000107A2/pt not_active IP Right Cessation
- 2011-07-22 TW TW100126062A patent/TW201217380A/zh unknown
- 2011-07-22 WO PCT/EP2011/062683 patent/WO2012010704A1/fr active Application Filing
- 2011-07-22 CA CA2803467A patent/CA2803467A1/fr not_active Abandoned
- 2011-07-22 MA MA35577A patent/MA34389B1/fr unknown
- 2011-07-22 KR KR1020137003430A patent/KR20130132394A/ko not_active Application Discontinuation
- 2011-07-22 PE PE2013000125A patent/PE20131143A1/es not_active Application Discontinuation
- 2011-07-22 MX MX2013000821A patent/MX2013000821A/es active IP Right Grant
- 2011-07-22 AP AP2012006640A patent/AP2012006640A0/xx unknown
- 2011-07-22 CN CN201180043930XA patent/CN103097388A/zh active Pending
- 2011-07-22 EP EP11734158.6A patent/EP2595987B1/fr active Active
- 2011-07-22 JP JP2013520164A patent/JP5991974B2/ja active Active
-
2012
- 2012-12-28 CL CL2012003745A patent/CL2012003745A1/es unknown
-
2013
- 2013-01-22 CO CO13011464A patent/CO6670575A2/es active IP Right Grant
- 2013-02-19 EC ECSP13012448 patent/ECSP13012448A/es unknown
Also Published As
Publication number | Publication date |
---|---|
US8735386B2 (en) | 2014-05-27 |
CA2803467A1 (fr) | 2012-01-26 |
BR112013000107A2 (pt) | 2016-05-17 |
ECSP13012448A (es) | 2013-03-28 |
JP2013532652A (ja) | 2013-08-19 |
US20120238542A1 (en) | 2012-09-20 |
TW201217380A (en) | 2012-05-01 |
MX2013000821A (es) | 2013-05-30 |
EP2595987A1 (fr) | 2013-05-29 |
KR20130132394A (ko) | 2013-12-04 |
WO2012010704A1 (fr) | 2012-01-26 |
JP5991974B2 (ja) | 2016-09-14 |
CL2012003745A1 (es) | 2013-05-31 |
AU2011281504A1 (en) | 2013-01-10 |
AR082850A1 (es) | 2013-01-16 |
UY33526A (es) | 2012-02-29 |
PE20131143A1 (es) | 2013-10-23 |
EA201201661A1 (ru) | 2013-07-30 |
CO6670575A2 (es) | 2013-05-15 |
AP2012006640A0 (en) | 2012-12-31 |
CN103097388A (zh) | 2013-05-08 |
EP2595987B1 (fr) | 2018-04-18 |
SG187548A1 (en) | 2013-03-28 |
GEP20156289B (en) | 2015-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34389B1 (fr) | Nouvelles aminopyrazoloquinazolines | |
CO6852084A2 (es) | Nuevos compuestos sustituidos con halógeno | |
MA37940A2 (fr) | Nouveaux dérivés bicycliques | |
CY1119515T1 (el) | Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης | |
CY1119105T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
CR20130045A (es) | Compuestos terapéuticos | |
MA35089B1 (fr) | Inhibiteurs de la production de leucotrienes de type benzodioxane | |
MA35664B1 (fr) | Nouveaux dérivés bicycliques de la dihydroisoquinoline-1-one | |
UA111626C2 (uk) | Похідні дигідрохінолін-2-ону | |
CR20120295A (es) | Triazolopiridinas | |
CR20130369A (es) | Novedosos derivados heterocíclicos | |
MA35357B1 (fr) | Composes de type anilines | |
UY34445A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
UY34177A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a | |
MA35049B1 (fr) | Triazolopyridines | |
CR20120113A (es) | (heteroarilmetil)tiohidantoinas sustituidas como drogas anticancer | |
UA110338C2 (en) | Chemical compounds | |
UY34825A (es) | Síntesis de compuestos heterocíclicos | |
TR201900038T4 (tr) | GPR6'nın tetrahidropiridopirazin modülatörleri. | |
CR20120297A (es) | Espironucleósidos uracílicos oxetánicos | |
CR20120637A (es) | Triazolopiridinas sustituidas | |
AU2011232516A8 (en) | Chemical compounds | |
CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
EA200900945A1 (ru) | Новый способ синтеза агомелатина | |
ECSP11011244A (es) | Nuevos herbicidas. |